Table II.
Patient Characteristics for Cohort by Age at Diagnosis (≤ 90 days, > 90 days)
| Overall Total n (%) |
Cohort 3 (N=141)
|
|||
|---|---|---|---|---|
| ≤ 90 days of age n (%) |
> 90 days of age n (%) |
p-value (age comparison for Cohort 3) | ||
|
Race | ||||
| Black | 9 (6.4) | 3 (11.1) | 6 (5.3) | |
| White | 115 (81.6) | 21 (77.8) | 94 (82.5) | 0.58 |
| Other/Unknown | 17 (12.1) | 3 (11.1) | 14 (12.3) | |
|
Gender | ||||
| Male | 80 (56.7) | 18 (66.7) | 62 (54.4) | 0.29 |
| Female | 61 (43.3) | 9 (33.3) | 52 (45.6) | |
|
WBC | ||||
| < 50K | 40 (28.4) | 1 (3.7) | 39 (34.2) | |
| 50K – 299K | 58 (41.1) | 10 (37.0) | 48 (42.1) | 0.0002 |
| ≥300K | 43 (30.5) | 16 (59.3) | 27 (23.7) | |
|
CNS status at diagnosis | ||||
| CNS 1 | 73 (51.8) | 4 (14.8) | 69 (60.5) | |
| CNS 2 | 45 (31.9) | 12 (44.4) | 33 (29) | <0.0001 |
| CNS 3 | 23 (16.3) | 11 (40.7) | 12 (10.5) | |
|
CD 10 status | ||||
| CALLA + | 21 (14.9) | 2 (7.4) | 19 (16.7) | 0.64 |
| CALLA − | 17 (12.1) | 3 (11.1) | 14 (12.3) | |
|
MLL status | ||||
| MLL-R | 100 (70.9) | 22 (81.5) | 78 (68.4) | 0.22 |
| MLL-G | 35 (24.8) | 4 (14.8) | 31 (27.2) | |
|
Death (first event) | ||||
| Induction death | 8 (5.7) | 4 (14.8) | 4 (3.5) | 0.35 |
| Remission death | 13 (9.2) | 3 (11.1) | 10 (8.8) | |
*
Note: 110 patients with missing CD10 status; 5 patients with unknown/missing MLL status